Background:
Upper Tract Urothelial Carcinoma (UTUC) is a type of cancer that develops in the lining of the kidney or ureter (the tube that connects the kidney to the bladder). Standard treatments often involve surgery to remove part or all of the kidney and ureter, which can significantly affect kidney function. For patients with low-grade (slow-growing) UTUC, there is growing interest in non-surgical, kidney-sparing treatments.
This clinical trial is studying a new investigational treatment called ST-02, which contains gemcitabine as its active ingredient. Gemcitabine is a chemotherapy drug that is already used safely and effectively in other forms of urothelial (bladder) cancer. ST-02 is a new formulation that allows the drug to stay longer in contact with the tumor inside the kidney or ureter, potentially improving its effectiveness.
The Trial:
In this study, ST-02 will be delivered directly into the upper urinary tract (where the tumor is located). Treatment will be given once a week for six weeks.
The main goals of the study are to find out:
- Whether ST-02 can completely remove (eradicate) the tumor within three months, and
- Whether it is safe and well-tolerated
All participants will be receiving the same treatment.
The trial is not “blind”, so both you and your doctor will know which therapy you are receiving.
Basic Eligibility:
- 18 years or older
- Have a low grade urothelial carcinoma of the renal pelvis, infundibulum, or calyces
- Have at least one visible papillary tumor that is 5–15 mm in size
Additional eligibility criteria will apply. Please speak to your doctor.
| Hospital / Cancer Centre | Principal Investigator | Location | Trial Status |
|---|---|---|---|
| Hospital / Cancer CentreVancouver Prostate Centre | Principal InvestigatorPeter Black | LocationVancouver, BC | Trial StatusRecruiting |
| Hospital / Cancer CentreMen’s Health Clinic | Principal InvestigatorJasmir Nayak | LocationWinnipeg, MB | Trial StatusRecruiting |
| Hospital / Cancer CentreCentre of Applied Urology Research | Principal InvestigatorRicardo Rendon | LocationHalifax, NS | Trial StatusRecruiting |
| Hospital / Cancer CentrePrincess Margaret Cancer Centre | Principal InvestigatorGirish Kulkarni | LocationToronto, ON | Trial StatusRecruiting |

























































